Wednesday , March 29 2017
Home / Rheumatoid Arthritis

Rheumatoid Arthritis

Scientists Discover New Mechanism that Leads to Inflammation in Rheumatoid Arthritis

New research findings published in the Journal of Leukocyte Biology, suggest that synovial CD4+ T cells that produce IL-21 contribute to joint inflammation by activating synovial fibroblasts in rheumatoid arthritis patients. Understanding the mechanisms of inflammation in rheumatoid arthritis is important for the design of new therapies for this disease. …

Read More »

New Assay May Lead to a Cure for Debilitating Inflammatory Joint Disease

Current treatments for rheumatoid arthritis relieve the inflammation that leads to joint destruction, but the immunologic defect that triggers the inflammation persists to cause relapses, according to research conducted at NYU Langone Medical Center and the University of Pittsburgh. Known as autoantibodies and produced by the immune system’s B cells, …

Read More »

Pfizer Announces Top-Line Results from the Oral Strategy Trial of Xeljanz Compared to Humira

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ® (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid arthritis (RA). ORAL Strategy is the first trial to compare a JAK inhibitor as monotherapy or in combination …

Read More »

Research Uncovers Bacteria Linking Crohn’s Disease to Arthritis

Patients with Crohn’s disease, a type of inflammatory bowel disease (IBD) that causes abdominal pain and diarrhea, can also experience joint pain. In Crohn’s disease, which affects about 800,000 Americans, the immune system can attack not only the bowels, but the musculoskeletal system as well, leading to spondyloarthritis, a painful …

Read More »

FDA and EMA Accept Boehringer Ingelheim’s Biosimilar Candidate to Humira for Review

Ingelheim, Germany, January 18, 2017 – Boehringer Ingelheim announced today that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by the European Medicines Agency (EMA) and the U.S Food and Drug Administration (FDA). “We believe that if approved, BI 695501 can provide a valuable …

Read More »

FDA Extends Review Period for Investigational Rheumatoid Arthritis Drug Baricitinib

INDIANAPOLIS, Jan. 13, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib, a once-daily oral medication for the treatment of moderate …

Read More »

Invisible Symptoms Impact Rheumatoid Arthritis Patients’ Lives, Hinder Diagnosis

Philadelphia, Dec. 14, 2016 – Rheumatoid Arthritis In America 2016, a national survey by Health Union of more than 3,100 individuals who identified as having rheumatoid arthritis (RA), reveals that initial symptoms are often invisible to others, with respondents experiencing more than six on average. A summary infographic is also …

Read More »

Fibroblasts Could Provide New Target for Treatment of Rheumatoid Arthritis

A study led by researchers at the University of Birmingham reveals the key role of different types of fibroblast cells in the development of rheumatoid arthritis (RA), opening up a new avenue for research into treatment of the disease. Synovial Fibroblasts (SFs) are cells that make up part of the …

Read More »

Celltrion Presents New Data Supporting Efficacy and Safety of its Biosimilars

WASHINGTON–(BUSINESS WIRE)–New data presented today at the 2016 American College of Rheumatology (ACR) Annual Meeting demonstrate that the efficacy and safety profile of CT-P10 (biosimilar rituximab) in rheumatoid arthritis (RA) patients is comparable to patients treated with originator rituximab over 24 weeks.1,2 A total of 372 RA patients (161 patients …

Read More »

Pfizer Presents Additional Research for Xeljanz in Rheumatologic Diseases

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today that 20 abstracts for XELJANZ® (tofacitinib citrate) will be presented at the upcoming 2016 ACR/ARHP Annual Meeting (November 11-16, Washington, DC). Notably, results from the two pivotal Phase 3 OPAL (Oral Psoriatic Arthritis TriaL) studies of tofacitinib – the only Janus kinase (JAK) …

Read More »